Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis
Journal of Clinical Oncology - United States
doi 10.1200/jco.2010.28.0198
Full Text
Open PDFAbstract
Available in full text
Date
October 10, 2010
Authors
Publisher
American Society of Clinical Oncology (ASCO)